Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.47 |
| ▸ | FNTB | P49356 | 4/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 6/20 | 0.44 |
| ▸ | NPY1R | P25929 | 4/20 | 0.44 |
| ▸ | NPY2R | P49146 | 3/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360283 | 0.92 | GNPAT (0.52) | GNPATSMN1; SMN2KISS1RNPY4RNPY1R | |
| SCHEMBL30045721 | 0.88 | KISS1R (0.55) | FNTAFNTBPGGT1BGNPATKISS1R | |
| SCHEMBL24178267 | 0.86 | SIRT5 (0.38) | FNTAFNTBPGGT1BNPY4RNPY1R | |
| SCHEMBL24178266 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATPTPN1 | |
| SCHEMBL24178265 | 0.85 | GNPAT (0.52) | FNTAFNTBPGGT1BGNPATPTPN1 | |
| SCHEMBL7368582 | 0.84 | GNPAT (0.48) | GNPATSMN1; SMN2KISS1RNPY4RNPY1R | |
| SCHEMBL24178180 | 0.83 | BACE1 (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL24178182 | 0.83 | BACE1 (0.44) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21167756 | 0.83 | F2 (0.50) | SMN1; SMN2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL13563435 | 0.82 | KISS1R (0.62) | GNPATKISS1RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | YALE UNIVERSITY (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | YALE UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912742-B2 | Heterologous production of leupeptin protease inhibitors and analogs thereof | LPXN, LAP3, PEPD | FNTA 2531/4885FNTB 1483/4885PGGT1B 2710/4885 |
| US-20220002354-A1 | HETEROLOGOUS PRODUCTION OF LEUPEPTIN PROTEASE INHIBITORS AND ANALOGS THEREOF | LPXN, LAP3, PEPD | FNTA 2531/4885FNTB 1483/4885PGGT1B 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.